Asklepios BioPharmaceutical, based on work by UNC Chapel Hill professors Jude Samulski and Xiao Xiao, has secured $235m in funding co-led by TPG Capital and Vida Ventures.
Varian led a round for the targeted cancer drug developer that included existing investors such as Facit and Johnson & Johnson.
Stanford-founded AI application platform developer SambaNova has raised $150m in a series B round led by Intel Capital that also featured existing investor GV.
GV participated as a new investor, as Harvard's genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.
GV and Alexandria have taken part in a $191m round to launch Maze Therapeutics with scientific co-founders from multiple universities such as Harvard and Stanford.
Passage Bio will develop therapies for diseases affecting the central nervous system based on research by James Wilson at Penn, after raising almost $116m in a series A round.